Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of RaQualia Pharma Inc.. A complete text table follows the diagram.
Business expenses reached JPY1.726 billion, including JPY782 million of R&D, while K-CAB sales grew 14.3% in Korea and reached 54 countries.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research & development expenses | 1 | 782M | 45.3% of reported total |
| Other selling, general & administrative expenses | 1 | 555M | 32.1% of reported total |
| Cost of business revenue | 1 | 389M | 22.5% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Business expenses | 2 | 1.7B | Reported six-month total · ¥1.7B |
| Operating loss | 2 | 190M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.9B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research & development expenses | Business expenses | 782M |
| Other selling, general & administrative expenses | Business expenses | 555M |
| Cost of business revenue | Business expenses | 389M |
| Other & rounding | Business expenses | 0 |
| Business expenses | Operating costs & expenses | 1.7B |
| Operating loss | Operating costs & expenses | 190M |